Abstract
Dapagliflozin is a representative of a new group of peroral antidiabetics based on inhibition of the SGLT2 receptor in the proximal renal tubule. Induced glycosuria then leads to a decrease in blood glucose, weight loss and blood pressure.
The efficacy and safety of dapagliflozin in both monotherapy and combination therapy has been demonstrated in a number of clinical trials. Moreover, the meta-analysis of the Phase III studies has shown a neutral effect of dapagliflozin on MACE (combined endpoint: cardiovascular death, non-fatal myocardial infarction and stroke) and reduced hospitalization for heart failure.
In addition, the efficacy of dapagliflozin has been confirmed recently by a large-scale "real clinical practice" trial.